Sialic Acid Extended Release in Patients with GNE Myopathy скачать в хорошем качестве

Sialic Acid Extended Release in Patients with GNE Myopathy

Ed Conner, M.D. Executive Medical Director, Ultragenyx Pharmaceutical Safety and Efficacy Data from a Randomized, Controlled Phase 2 Study (Including Long Term 2 Year Data) of Sialic Acid Extended Release in Patients with GNE Myopathy Sixth Annual Rare Disease Day Symposium Treating Disease with Sugars Sanford-Burnham Medical Research Institute February 27, 2015 Dr. Ed Conner is an Executive Medical Director at Ultragenyx Pharmaceutical and is the medical lead for the program using extended release sialic acid to treat GNE Myopathy. Prior to joining Ultragenyx, Ed was at BioMarin where he was the clinical lead for the BMN 701 program, a replacement therapy for the treatment of late onset Pompe disease. Prior to that, he worked at Genentech for over 5 years where he worked on both early and late stage programs in infectious diseases, allergy, and immunology. Ed earned his BS in Biology from Duke University and his MD from the University of California, San Francisco. He did his training in Internal Medicine from the University of Michigan and completed his fellowship in Clinical Immunology & Allergic Diseases from Johns Hopkins University.